# Study to Compare 2 Formulations of LY900014 in Healthy Participants

> **NCT03616977** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 69 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY900014 U-200
- **DRUG:** LY900014 U-100

## Key facts

- **NCT ID:** NCT03616977
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-03
- **Primary completion:** 2018-10-19
- **Final completion:** 2018-10-19
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2020-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616977, "Study to Compare 2 Formulations of LY900014 in Healthy Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03616977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*